An evaluation of the Xpert MTB/RIF assay and detection of false-positive rifampicin resistance in Mycobacterium tuberculosis

Diagnostic Microbiology and Infectious Disease

Volumn 74, Issue 2, 2012, Pages 207-209

  Williamson, Deborah A ^a   Basu, Indira ^a   Bower, James ^a   Freeman, Joshua T ^a   Henderson, Gillian ^a   Roberts, Sally A ^a  

^a AUCKLAND DISTRICT HEALTH BOARD   (New Zealand)

Author keywords

Mycobacterium tuberculosis; Resistance; Rifampicin; Xpert MTB RIF assay

Indexed keywords

ALANINE; ASPARAGINE; GLYCINE; HISTIDINE; ISOLEUCINE; LEUCINE; METHIONINE; PROLINE; RIFAMPICIN; SERINE; TYROSINE; VALINE;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; ASSAY; BACTERIAL GENE; BACTERIUM CULTURE; BACTERIUM DETECTION; CONTROLLED STUDY; FALSE POSITIVE RESULT; GENE AMPLIFICATION; GENE MUTATION; GOLD STANDARD; INTERMETHOD COMPARISON; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; RPOB GENE; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS;

ANTITUBERCULAR AGENTS; BACTERIOLOGICAL TECHNIQUES; DRUG RESISTANCE, BACTERIAL; FALSE POSITIVE REACTIONS; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; MYCOBACTERIUM TUBERCULOSIS; RIFAMPIN; SENSITIVITY AND SPECIFICITY; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84866156554     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2012.06.013     Document Type: Article

References (10)

1. Alonso M., Palacios J.J., Herranz M., et al. Isolation of Mycobacterium tuberculosis strains with a silent mutation in rpoB leading to potential misassignment of resistance category. J Clin Microbiol 2011, 49:2688-2690.
2. Boehme C.C., Nabeta P., Hillemann D., et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 2010, 363:1005-1015.
3. Boehme C.C., Nicol M.P., Nabeta P., et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 2011, 377:1495-1505.
4. Lawn S.D., Brooks S.V., Kranzer K., et al. Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective study. PLoS Med 2011, 8:e1001067.
5. Moure R., Martín R., Alcaide F. Silent mutation in rpoB detected from clinical samples with rifampin-susceptible Mycobacterium tuberculosis. J Clin Microbiol 2011, 49:3722.
6. Scott L.E., McCarthy K., Gous N., et al. Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study. PLoS Med 2011, 8:e1001061.
7. Siddiqi S.H., Rüsch-Gerdes S. MGIT Procedure manual 2006, Foundation for Innovative New Diagnostics, Geneva, Switzerland.
8. Telenti A., Imboden P., Marchesi F., et al. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 1993, 341:647-650.
9. Trébucq A., Enarson D.A., Chiang C.Y., et al. Xpert® MTB/RIF for national tuberculosis programmes in low-income countries: when, where and how?. Int J Tuberc Lung Dis 2011, 15:1567-1572.
10. Williamson D.A., Roberts S.A., Bower J.E., et al. Clinical failures associated with rpoB mutations in phenotypically occult multidrug-resistant Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2012, 16:216-220.